Secondary analysis of two randomised trials in 90 adults with active IBD and iron deficiency: baseline hepcidin predicted response to oral ferrous fumarate (AUC 0.86) but less clearly to IV iron (AUC 0.63, 95% CI 0.30–0.96); hepcidin >2.68 μg/mL flagged non-responders.
Secondary analysisn = 90
Koppelman et al. Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial